Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Endothelin antagonists part of Fujisawa's pipeline

July 12, 1996

Na+/K+-ATPase inhibitors revealed by Sigma-Tau

July 12, 1996

M2 antagonists reported by Yamanouchi

July 5, 1996

Kyowa Hakko's OXT displays cardiotonic and insulin release-promoting effects

July 5, 1996

NEP inhibitors claimed by Santen

July 5, 1996

AHP describes tricyclic benzazepine vasopressin antagonists

July 5, 1996

Alexion begins phase I testing of 5G1.1-SC

July 5, 1996

TMR with PLC Systems' Heart Laser continues to display efficacy

July 5, 1996

First launch for Ciba-Geigy angiotensin II antagonist

July 5, 1996

Warner-Lambert reports nonpeptide ET antagonists

July 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.